Activist investor William Ackman of Pershing Square Capital and Valeant Pharmaceuticals International are teaming up to pursue a takeover of Allergan. Allergan shares rose 13 percent on the news.
Valeant, in a filing with the Securities and Exchange Commission, said it expected to offer a mix of stock and about $15 billion in cash for the Botox maker.
Barclays and RBC are lined up to finance the cash portion. Sources told CNBC the deal's total value would be slightly more than $45 billion.
Allergan declined to comment. Click here to see what Allergan's shares are doing now.
Dow Jones first reported the news Monday afternoon.
Read More AstraZeneca cancer pipeline likely draw for Pfizer
Pershing Square, which declined to comment, holds a nearly 10 percent stake in Allergan. The pharma company is best-known for its cosmetology blockbuster Botox.
The SEC filing indicated that Ackman and Valeant agreed in late February to pursue Allergan. Ackman also agreed to hold at least $1.5 billion worth of Valeant shares for one year after the closing of an Allergan merger.